735 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More http://www.zacks.com/stock/news/501326/biotech-stock-roundup-regn-wins-against-amgn-vrtx-to-acquire-semma-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-501326 Sep 04, 2019 - Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Company News for Aug 27, 2019 http://www.zacks.com/stock/news/490987/company-news-for-aug-27-2019?cid=CS-ZC--corporate_summary-490987 Aug 27, 2019 - Companies in the news are: AMGN, PBI, BYND, SRCI, PDCE
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676 Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Big Drugmakers That May Tread the M&A Path After Pfizer http://www.zacks.com/stock/news/431504/big-drugmakers-that-may-tread-the-ma-path-after-pfizer?cid=CS-ZC-FT-431504 Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Top Analyst Reports for Broadcom, Amgen & NVIDIA http://www.zacks.com/research-daily/431127/top-analyst-reports-for-broadcom-amgen-nvidia?cid=CS-ZC-FT-431127 Jun 18, 2019 - Top Analyst Reports for Broadcom, Amgen & NVIDIA
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors http://www.zacks.com/stock/news/431013/roches-rozlytrek-gets-approval-in-japan-for-solid-tumors?cid=CS-ZC-FT-431013 Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal https://www.fool.com/investing/2019/06/18/3-big-drugmakers-most-likely-to-make-acquisitions.aspx?source=iedfolrf0000001 Jun 18, 2019 - Pfizer could be only the first of several to spend billions buying smaller biotech.
3 Stocks to Buy and Hold for the Next 50 Years https://www.fool.com/investing/2019/06/16/3-stocks-to-buy-and-hold-for-the-next-50-years.aspx?source=iedfolrf0000001 Jun 16, 2019 - When your time frame is decades, you need to look differently at an investment. Here are three that can stand the test of time.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti http://www.zacks.com/stock/news/429548/amgen-allergan-get-fda-nod-for-herceptin-biosimilar-kanjinti?cid=CS-ZC-FT-429548 Jun 14, 2019 - FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338 Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

Pages: 12345678910...74

<<<Page 5>